<i>BRAF</i> V600E mutation detected in a case of Rosai-Dorfman disease

Giancarlo Fatobene, Julien Haroche, Zofia Hélias-Rodzwicz, Frédéric Charlotte, Valérie Taly, Aliana Meneses Ferreira, André Abdo, Vanderson Rocha, Jean‐François Emile

Haematologica · 2018 · 62 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

Rosai-Dorfman Disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is a rare, nonmalignant histiocytic proliferation of unknown etiology. According to the new classification, it belongs to the R group of histiocytoses. 1 The clinical course of this disease is quite unpredictable with alternating episodes of worsening and reliving of symptoms. The outcome is usually good, and the disease is often self-limiting. Treatment for RDD is only advised in patients with symptomatic disease or who have a vital organ or system compromised. Common therapeutic modalities include surgery, corticosteroids, interferon, chemotherapy, immunotherapy, and radiotherapy. lthough most individuals with RDD have a benign clinical course, some cases are quite challenging, and optimal target therapeutic agents are missing. ] Apart from node enlargement, he had no other symptoms (fever, weight loss or night sweats). A node biopsy was obtained, and diagnosis of RDD was established.

References

15